Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Quick Stats
May 18, 202650.6
AI Score
HOLD0.45
Volume Ratio
May 13, 2026
Next Earnings
12
+ve Days (30d)
18
-ve Days (30d)
ACAD Stock Summary
Last updated May 18, 2026
ACAD is currently trading at $20.725, positioned below its 200-day moving average of $23.7, suggesting bearish momentum. The stock has a 52-week range of $18.37 to $28.35.
Technical Analysis: The 50-day moving average stands at $21.8, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 40.48, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.101, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates ACAD at 50.6/100 with a HOLD recommendation.
ACAD (Acadia Pharmaceuticals Inc.) Indicators
Last updated May 18, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 40.48 |
| CMF (20) | -0.101 |
| ROC (10) | -5.858 |
| ADX (14) | 16.753 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -0.139 |
| AROONOSC (14) | -57.143 |
| WILLAMS %R (14) | -91.213 |
| MFI (14) | 56.127 |
ACAD Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
ACAD Price vs Max Options Open Interest
ACAD Max Change In Options Open Interest
ACAD Options - Sort by Max open Interest (near term)
18th May 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
ACAD Daily Out of Money Options - Sort by Max open Interest (near term)
18th May 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
ACAD Daily In the Money Options - Sort by Max open Interest (near term)
18th May 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
ACAD Most Active Options by Volume(near term)
18th May 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
Acadia Pharmaceuticals Inc. is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
ACAD Moving Averages Analysis
ACAD (Acadia Pharmaceuticals Inc.) Simple Moving Averages
Moving Averages are last updated May 18, 2026
| Days | MA |
|---|---|
| 10 | 21.89 |
| 20 | 22.04 |
| 30 | 22.02 |
| 50 | 21.8 |
| 100 | 23.49 |
| 200 | 23.7 |
ACAD Fundamental Analysis
| P/E (Forward) | 64.9351 |
| P/E (Trailing) | 9.9955 |
| Market Cap ($) | 3.8 billion |
| Earnings/Share ($) | 2.21 |
| Net Proft Margin (%) | 0.343 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | 0.3972 |
| EPS Estimate Next Year ($) | 0.893 |
| WallStreet Target Price ($) | 31.65 |
| Most Recent Quarter |